SB-Kawasumi Laboratories Inc Sustainability Profile
SB-Kawasumi Laboratories Inc., headquartered in Japan, is a prominent player in the medical device and healthcare industry. Founded in 1975, the company has established itself as a leader in the development and manufacturing of high-quality medical products, particularly in the fields of dialysis and infusion therapy. With a strong presence in Asia and expanding operations globally, SB-Kawasumi is renowned for its innovative solutions, including advanced dialysis systems and infusion devices that prioritise patient safety and efficacy. The company’s commitment to research and development has led to significant milestones, positioning it as a trusted name in healthcare. Notable achievements include numerous certifications and partnerships that underscore its dedication to quality and excellence. SB-Kawasumi Laboratories continues to set industry standards, making a meaningful impact on patient care worldwide.
DitchCarbon Score
How does SB-Kawasumi Laboratories Inc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
SB-Kawasumi Laboratories Inc's score of 48 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
SB-Kawasumi Laboratories Inc, headquartered in Japan, currently does not report specific carbon emissions data for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of Sumitomo Bakelite Company Limited, which may influence its climate commitments and reporting practices. While there are no documented reduction targets or climate pledges directly attributed to SB-Kawasumi Laboratories Inc, it is important to note that any potential initiatives or targets may be inherited from its parent company, Sumitomo Bakelite Company Limited. This relationship suggests that the company's climate strategy could align with the broader sustainability goals set by its parent organisation. As of now, SB-Kawasumi Laboratories Inc has not disclosed specific initiatives or commitments towards reducing carbon emissions, nor has it provided any data on its Scope 1, 2, or 3 emissions. The lack of available data highlights a potential area for improvement in transparency regarding their environmental impact and climate action strategies.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 90,643,000 | 00,000,000 | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 145,869,000 | 000,000,000 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 |
How Carbon Intensive is SB-Kawasumi Laboratories Inc's Industry?
How Carbon Intensive is SB-Kawasumi Laboratories Inc's Location?
SB-Kawasumi Laboratories Inc's Scope 3 Categories Breakdown
SB-Kawasumi Laboratories Inc's Scope 3 emissions, which decreased by 79% last year and decreased by approximately 80% since 2021, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 76% of Scope 3 emissions.
Top Scope 3 Categories
SB-Kawasumi Laboratories Inc's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
SB-Kawasumi Laboratories Inc has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Outset Medical, Inc.
Bain Medical Equipment (Guangzhou) Co. Ltd
Nipro
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.